secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2026-05-14T20:05:17+00:00
Accession:  0001493152-26-023059
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones
--------------------------------------------------------------------------------

- Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.
- Net loss $9.1M ($4.06/share) vs $7.5M ($7.05/share); adjusted EBITDA loss $8.7M.
- Cash $8.2M at Mar 31, 2026, down from $11.9M at Dec 31, 2025.
- Received CDSCO license for CoSara PCR Pro instrument in India; ISO 13485 certification for manufacturing facility.
- Completed enrollment in upper respiratory test clinical study with >1,400 patients; advancing TB study in India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/0001493152-26-023059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer